Ozanimod
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Ozanimod
Ozanimod: Known uses and market status in Canada
Summary
All candidates produced by the TxGNN model for Ozanimod that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use found is recorded as a knowledge graph relation, not as an approval. This page is for research reference only and is not medical advice.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| progressive relapsing multiple sclerosis |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02506009 | ZEPOSIA | Valid | |
| 02505991 | ZEPOSIA | Valid |
Safety Considerations
- Contraindications suggested by the knowledge graph (these come from drug-disease relationship data, not package insert text, and need to be checked against the label):
- Sleep-related breathing disorders: obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome
- Cerebrovascular disease: stroke disorder, cerebrovascular disorder, cerebral infarction, transient ischemic attack, vertebrobasilar insufficiency
- Cardiac disease: myocardial infarction, coronary thrombosis, intermediate coronary syndrome, congestive heart failure, heart failure
- Conduction disorders: sick sinus syndrome (including familial), atrioventricular block, sinoatrial block
- Hemoglobinopathy
- Drug Interactions: 100 interactions were found in the DDI database; 20 are listed in the data compiled for this report, of which the Major ones include:
- Isometheptene, famotidine, bupropion, morphine, lorcaserin, clarithromycin, diethylpropion, phentermine
- Corticosteroids: hydrocortisone, triamcinolone, betamethasone, budesonide
- Antiemetics: dolasetron, palonosetron
- Moderate interactions include ranitidine, cimetidine, epinephrine, loperamide, picosulfuric acid and polyethylene glycol (3350 with electrolytes).
Please refer to the package insert for the full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.